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Hantaviruses are associated with two human diseases, hemorrhagic fever with renal syndrome (HFRS) and hanta-
virus pulmonary syndrome (HPS). Development of vaccines and therapies to prevent and treat HFRS and HPS have
been hampered by the absence of a practical animal model. Here we report that Andes virus (ANDV), a South Ameri-
can hantavirus, is highly lethal in adult Syrian hamsters. The characteristics of the disease in hamsters, including the
incubation period, symptoms of rapidly progressing respiratory distress, and pathologic findings of pulmonary edema and
pleural effusion, closely resemble HPS in humans. This is the first report of a lethal disease model for hantaviruses that
causes HPS.In 1993 an outbreak of a previously unrecognized dis-
ease occurred in the southwestern United States, char-
acterized by an influenza-like prodrome, followed by
rapid onset of severe respiratory distress, pulmonary
edema, and shock. The case-fatality rate for the initial
outbreak (24 patients, most of whom were healthy young
adults) was 50% (1). Serological testing revealed that the
patients had antibodies that cross-reacted with antigens
from hantaviruses. Sequence analysis of RT-PCR prod-
ucts from autopsy specimens confirmed that the patients
were infected with a previously unrecognized hantavirus
(2). Virus isolates were obtained from tissues of deer
mice (Peromyscus maniculatus) that had been captured
in or around the dwellings of patients with severe respi-
ratory illness in New Mexico (Muerto Canyon virus) (3)
and California (Convict Creek virus) (4). These viruses
were later collectively renamed Sin Nombre virus (SNV),
and the disease, hantavirus pulmonary syndrome (HPS).
Two years later, a series of HPS outbreaks in Chile and
Argentina were reported. The causative agent, from a
fatal case, was identified by genetic methods and was
named Andes virus (ANDV) (5). ANDV has caused ;400
cases of HPS in Chile and Argentina and is the only
hantavirus for which there is persuasive evidence of
person-to-person transmission (6). Since 1993, out-
breaks of HPS involving ;700 patients, caused by at
least 10 different hantaviruses, have occurred throughout
North, Central, and South America. Despite intensive
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6hospital care, case-fatality rates for HPS outbreaks re-
main high (30–45%). There is no vaccine or effective
antiviral drug to prevent or treat HPS.
Hantaviruses are members of the genus Hantavirus,
family Bunyaviridae (7). These enveloped viruses have a
trisegmented, negative-sense, single-stranded RNA ge-
nome. The small (S) segment encodes the nucleocapsid
protein; the medium (M) segment encodes the surface
glycoproteins (G1 and G2), and the large (L) segment
encodes the RNA-dependent RNA polymerase. The gly-
coproteins, G1 and G2, but not the nucleocapsid protein,
are targets of neutralizing antibodies (NAbs). Hantavi-
ruses are carried by chronically infected rodents and are
transmitted to humans who may inhale aerosolized ro-
dent excreta.
In addition to the HPS-associated hantaviruses, there
are four hantaviruses [Hantaan virus (HTNV), Seoul virus
(SEOV), Dobrava virus (DOBV), and Puumala virus
(PUUV)] associated with a disease called hemorrhagic
fever with renal syndrome (HFRS). HFRS-associated han-
taviruses and their hosts are found predominantly in
Europe and Asia, whereas HPS-associated hantaviruses
and their hosts are present only in the Americas. The
initial influenza-like symptoms are similar between HFRS
and HPS; however, these symptoms in HFRS are fol-
lowed by renal impairment and sometimes by hemor-
rhagic manifestations such as petechiae. Case-fatality
rates of HFRS range from 0.1–15%, depending on the type
of hantavirus involved and the care the patient receives.
Tens of thousands of HFRS cases are reported each
year, mostly in China.There is no practical disease model to study either














7RAPID COMMUNICATIONvaccines and therapies to prevent and treat these dis-
eases. Hantaviruses cause lethal disease in newborn
rodents such as mice (8); however, the disease does not
resemble the disease in humans and the age require-
ment for lethality makes the newborn rodent model un-
amenable for experiments involving active vaccination.
There are reports of subtle histopathologic lesions in
some of the natural hosts of certain HPS-hantaviruses;
however, there are no overt symptoms of disease and no
lethality (9, 10). HFRS-hantaviruses can infect several
species of New and Old World monkey species and two
ape species but the animals tested remained asymptom-
atic except for a mild proteinuria and slight rise in liver
enzymes (11, 12). The mild disease, as well as economic
considerations inherent to nonhuman primate studies,
renders these models impractical for most studies.
To evaluate the efficacy of candidate hantavirus vac-
cines, investigators have used infection models rather
than disease models. For example, we have used a
hamster infection model to study the immunogenicity
and protective efficacy of DNA vaccines against the
HRFS-associated hantaviruses (13). In this system, vac-
cinated hamsters are challenged intramuscularly (im)
with a defined dose of hantavirus and 28 days later,
serological assays are performed to detect evidence of
infection. An infection model is used because HFRS-
hantaviruses do not cause disease in hamsters even at
doses as high as 20,000 plaque-forming units (PFU).
Results and Discussion. Andes virus is lethal in adult
hamsters. To prepare for future studies evaluating vac-
ines against HPS-hantaviruses, we sought to determine
he dose infecting 50% of the hamsters (ID50) for the two
antaviruses that are responsible for the overwhelming
ajority of HPS cases in North and South America, SNV
nd ANDV, respectively. Groups of six to eight hamsters
ere injected im with serial 10-fold dilutions (from 20,000
o 2 PFU) of ANDV or SNV. To rule out the possibility that
eroconversion was caused by input virus, rather than an
ctive infection, eight hamsters were injected with
0,000 PFU of g-irradiated (3 3 106 rad) SNV or ANDV.
Our initial plan was to obtain blood 28 days after chal-
lenge and then perform serological assays to detect
evidence of infection and calculate ID50 values. Unex-
pectedly, hamsters injected with ANDV began to die 11
days postinfection (Fig. 1a). There were no overt clinical
changes until less than 24 h before the hamsters suc-
cumbed to the viral infection. During the hours before
death, the hamsters became moribund and appeared to
be in respiratory distress, as indicated by severe dys-
pnea. Death occurred within 5–18 h after initial signs of
distress. Hamsters injected with the highest doses of
virus died the earliest (all hamsters injected with $200
PFU died within 2 weeks of challenge). One hamster
injected with 2 PFU of virus died 24 days after challenge.
From these data, the lethal dose required to kill 50% ofthe hamsters (LD50) was calculated to be 8 PFU. Infection
was not uniformly fatal because two hamsters that sur-
vived the challenge showed serological evidence of in-
fection as measured by antinucleocapsid ELISA and a
plaque-reduction neutralization test (PRNT). The anti-
nucleocapsid endpoint titers were 12,800 and 6400 and
the PRNT80% titers were 640 and 320, respectively. From
these data, the ANDV ID50 was calculated to be 3 PFU. All
f the hamsters injected with the irradiated ANDV sur-
ived and remained seronegative by both ELISA and
RNT. Thus, our experiment to determine the ANDV ID50
FIG. 1. ANDV is highly lethal in hamsters, SNV is not. (a) Hamsters
were injected with the indicated virus at the indicated concentration
(see figure). The number of survivors on each day after virus injection
was determined. Days on which hamsters died are boxed. (b) To verify
SNV infection, serum was collected 28 days after virus injection and
was tested for antinucleocapsid antibodies by ELISA and NAb by
PRNT. End-point antibody titers for individual hamsters given the high-
est (20,000 PFU) and lowest (2 PFU) dose of SNV tested were deter-
mined. The GMT and standard deviation for each group are shown.resulted in the discovery that ANDV is highly lethal in

































8 RAPID COMMUNICATION$20 PFU of ANDV injected im was fatal in 93% of the
cases (n 5 58).
Lethality in hamsters is not a general property of HPS-
ssociated hantaviruses because the SNV-challenged
amsters showed no symptoms of disease even when
njected with a dose as high as 2 3 104 PFU (Fig. 1a). To
ook for evidence of infection, the SNV-infected hamsters
ere bled on day 28 as originally planned and anti-
ucleocapsid ELISA and PRNT were performed. Anti-
ody responses were elicited in all of the SNV-chal-
enged animals except a single hamster injected with 2
FU of virus. The serology data for the groups chal-
enged with the highest and lowest doses of SNV are
hown (Fig. 1b). Antibody responses did not depend on
he concentration of the input virus because equivalent
ntinucleocapsid ELISA and PRNT antibody titers were
licited in hamsters injected with 2 3 104 or 2 PFU of
SNV. Thus, SNV readily infected hamsters (ID50 , 2), but
did not cause disease. The molecular basis for the dif-
ferent pathogenesis (in hamsters) exhibited by these two
closely related (5) hantaviruses, as well as the pathogen-
esis of other ANDV variants and the other HPS-associ-
ated hantaviruses, remains to be determined.
To rule out the possibility that a contaminating patho-
gen, rather than ANDV, was responsible for the observed
lethality in hamsters, we prepared a twice-plaque-puri-
fied viral stock and compared it with the original virus.
Ten hamsters were injected with 2000 PFU of twice-
plaque-purified ANDV and 10 hamsters were injected
with 2000 PFU of the original ANDV stock. All of the
hamsters in both groups died after 10–14 days. The
mean time-to-death for the twice-plaque-purified virus,
day 11, was slightly earlier than the original virus, day 13
(P 5 0.001). This difference may be an artifact of small
ample size. Alternatively, it could indicate that the orig-
nal viral stock contains populations of ANDV with differ-
nt levels of virulence and the twice-plaque-purified virus
s at the more virulent end of the spectrum. The lethality
f the twice-plaque-purified ANDV indicated it was highly
nlikely that a contaminant in the original stock was
illing the animals.
Syrian hamsters, similar to humans, appear to be es-
ecially vulnerable to lethal ANDV-associated disease.
o determine whether other rodent species were sus-
FIG. 2. ANDV causes HPS in hamsters. (a) Diaphragm, hamster 210.
he congested and slightly enlarged liver. (b) Thoracic cavity, hamster 2
xposed to ANDV. Note the atelectasis of the right lung. (c) Quality c
pneumonia with prominent intraalveolar edema and fibrin. Note the inc
(3400). (e) Lung, hamster 162. Lung tissue demonstrating antigen staini
EnVision-AP system, anti-SNV rabbit antibody. HistoMark RED chromag
demonstrating viral antigen within endothelial cells. Vectastain AB
hematoxylin counterstain (31000). (g) Liver, hamster 158. Note the diffus
anti-SNV rabbit antibody. HistoMark RED chromagen with Hematoxyli
marginal zone. Note the peripheralized staining pattern in some cells (arrow).
chromagen with hematoxylin counterstain (3600).eptible to ANDV, we injected 2000 PFU of the twice-
laque-purified ANDV into ten 8- to 10-week-old female
ALB/c mice (NCI, Frederick, MD) by the same method
sed to inject hamsters. The mice showed no signs of
isease, but 9 of 10 were infected as indicated by a
ositive NAb response 35 days after virus injection
PRNT80% GMT 5 139).
Postmortem examination of hamsters that died as a
result of ANDV infection revealed a large volume (3–5 ml)
of a semiopaque yellow effusion present within the tho-
racic cavity (Figs. 2a and 2b). The lungs were variably
collapsed in some hamsters. The livers were consis-
tently congested and slightly enlarged in all hamsters.
There were no other visible signs of disease.
Histologically, the lung, liver, and spleen had the most
significant and consistent changes. All hamsters had a
mild to moderate subacute interstitial pneumonia with
intraalveolar edema, protein, and fibrin that multifocally
filled alveolar spaces and expanded alveolar septal
walls (Figs. 2c and 2d). The inflammatory component
consisted primarily of macrophages and lymphocytes
with lesser numbers of neutrophils within septal walls
and surrounded the larger blood vessels with an in-
creased number of alveolar macrophages in alveolar
spaces. The edema was often profound around the large
blood vessels with markedly dilated lymphatics and ex-
pansion of the perivascular interstitium. The lungs were
mildly to moderately congested and mesothelial cells
were often hypertrophied. There was a mild to moderate
subacute hepatitis in all hamsters. Randomly scattered
throughout the parenchyma were low numbers of hyper-
chromatic hepatocytes with irregular cellular borders
containing karyorrhectic debris. Increased numbers of
lymphocytes were occasionally present surrounding
larger vessels. The splenic red pulp of all hamsters was
expanded by abundant numbers of large round cells with
an increased cytoplasmic to nuclear ratio. The morphol-
ogy of these cells is consistent with that of previously
reported in human cases; however, the histogenesis has
not been fully elucidated. There were a variety of other
lesions present in this initial group of hamsters. Some of
these changes were considered background lesions
arising from autolysis after death; others warrant further
investigation.
rows outline a prominent fluid line delineated on the diaphragm. Note
tration of the abundant fluid present in the thoracic cavity of hamsters
amster. Normal lung. H&E (3400). (d) Lung, hamster 164. Interstitial
thickness of the alveolar septal walls relative to the normal lung. H&E
dothelial cells in the septal walls and an alveolar macrophage (arrow).
hematoxylin counterstain (3600). (f) Lung, hamster 164. Blood vessel
ystem, anti-ANDV human serum. HistoMark RED chromagen with
ften punctate staining pattern within hepatocytes. EnVision-AP system,








n counVectastain ABC-AP system, anti-ANDV human serum. HistoMark RED
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10 RAPID COMMUNICATIONImmunohistochemistry was performed on the lung,
liver, and spleen. Endothelial cells lining blood vessels
and alveolar septa and lesser numbers of alveolar mac-
rophages were positive for viral antigen (Figs. 2e and 2f).
Midzonal hepatocytes were abundantly stained with an-
tigen (Fig. 2g). Viral antigen in the spleen was present in
red pulp macrophages, endothelial cells, and in the mar-
ginal zone peripheral to follicular areas. The positive
cells in the marginal zone (see Fig. 2h) are consistent
FIG. 3. Virus and NAb in tissues of ANDV-infected hamsters. (a) Nec
of the hamsters died between 11 and 14 days after virus injection. Tis
infectious virus. Negative samples (limit of detection was 50 PFU/ml) a
injection, on days 5 and 8 after injection, and then on day 12 or 14 wh
the presence of infectious ANDV by plaque assay and for NAb by PRN
* indicates the moribund animal was euthanized.with those of antigen-presenting cells; however, immu-
noidentification of these cells is not yet complete. Side-by-side comparison demonstrated a similar staining pat-
tern for both anti-ANDV human antibody and anti-SNV
rabbit polyclonal antiserum, although the anti-SNV serum
generally elicited more robust staining.
To evaluate infectious virus in the organs of hamsters
that succumbed to ANDV infection, plaque assays were
performed on tissues collected at necropsy. Infectious
virus was detected in the lungs, liver, kidney, spleen,
heart, and small intestine, but not from the large intestine
were performed on hamsters that died after challenge with ANDV. All
mples were processed and plaque assays were performed to detect
esented as white bars. (b) Serum samples were collected before virus
ibund hamsters were euthanized. Serum samples were evaluated for
th panels, hamster identification numbers are shown under the x axis.ropsies
sue sa
re repr
en moror brain (Fig. 3a). The highest concentration of virus was
found in the liver. One liver sample (hamster 206) had a
S ter AND
i h occu
11RAPID COMMUNICATIONviral concentration of 3.1 3 108 PFU/ml, which is a con-
centration 10–100 times greater than routinely attained in
Vero E6 cell culture supernatants. To confirm that the
tissue-isolated virus was in fact ANDV, we performed
PRNT using human convalescent sera from HPS patients
from Argentina. Virus isolated from the liver was com-
pletely neutralized by HPS patient serum diluted 1:1280
and the PRNT80% was 5120. Thus, the organs of hamsters
that died as a result of infection not only contained ANDV
antigen, but also contained high concentrations of infec-
tious virus.
The large volume of pleural effusion that filled the
thoracic cavity of the infected hamsters did not contain
infectious ANDV at the time of necropsy (Fig. 3a). We
tested the pleural effusion for NAb by PRNT from four
different hamsters and found all were positive (PRNT80%
ranged from 20 to 640, GMT 5 160). To monitor the
relative levels of serum viremia and NAbs during the
course of infection, we collected serum samples at days
0, 5, 8, 12, and 14 after challenge and performed plaque
assays and PRNT (Fig. 3b). Infectious virus was first
detected in the serum on day 8, but was absent on day
12 or 14. In contrast, NAb was not detected until day 12
or 14. These data suggest that the hamster’s immune
system responded to the infection and was capable of
neutralizing a transient serum viremia. However, the im-
mune response failed to eliminate infectious virus from
the organs (Fig. 3a) and, in most cases, was insufficient
to protect against lethal disease. Liver, lung, and spleen
tissue homogenates from hamster 164 did not contain
FIG. 4. Previous immunity to homo- or heterotypic hantaviruses prot
naive hamsters, hamsters that had survived a previous ANDV challenge
collected and tested for NAb by PRNT. Homotypic NAb titers, as well a
with 2000 PFU of ANDV (im). After 28 days, postchallenge serum samp
ANDV-specific NAb PRNT50% titer before f and M after ANDV challenge
terile immunity was defined as the absence of ANDV-specific NAb af
mmunity are bold. A dagger (†) represents death of the hamster, whicinfectious virus, but tissue samples from the same or-
gans did contain viral antigen (Fig. 2f). This could indi-cate that the immune response in this hamster had
neutralized the ANDV not only in the serum but also in
the organs. An alternative trivial explanation is that the
virus in these samples from hamster 164 might have
been degraded and inactivated by proteases released
after the hamster died, or during sample preparation.
To determine whether or not previous infection with
heterotypic HFRS or HPS hantaviruses could confer pro-
tection against a lethal ANDV infection, groups of seven
to eight hamsters [14- to 16-week-old female Syrian ham-
sters (Charles River Laboratories, Inc., Wilmington, MA)]
were injected im (caudal thigh) with ;1000 ID50 of HTNV,
SEOV, DOBV, PUUV, or SNV, which was 2000 PFU for
HTNV, SEOV, DOBV, and SNV; 20,000 PFU of PUUV (un-
published data). After 4 weeks; the hamsters were chal-
lenged im with 2000 PFU of ANDV. Three hamsters that
had survived ANDV infection in an earlier experiment
and three naive hamsters were also challenged. Serum
samples were collected from all hamsters before ANDV
challenge and then from survivors 4 weeks after chal-
lenge. All of the hamsters survived except the naive
hamsters and two of eight DOBV-infected hamsters (Fig.
4). These data indicated that previous infection with a
heterotypic hantavirus elicited protective immunity
against ANDV and parenthetically reaffirmed that the
hamster-lethal agent was a hantavirus. Whether this pro-
tective immunity is directed toward the glycoproteins,
nucleocapsid protein, a combination of both proteins, or
neither (i.e., innate response) remains to be determined.
To begin to dissect the mechanism of the protective
ainst an otherwise lethal challenge with ANDV. Serum samples from
sters previously (28 days) infected with a heterotypic hantavirus were
V cross-NAb titers, were determined. Hamsters were then challenged
e collected from survivors and ANDV NAb titers were determined. The
he homotypic NAb PRNT80% titer before F ANDV challenge are shown.
V challenge. Identification numbers of hamsters that exhibited sterile




, and timmunity elicited by prior hantavirus infection, we per-






















12 RAPID COMMUNICATIONand after ANDV challenge. Although all of the hamsters
had homotypic PRNT titers before challenge, none of the
sera cross-neutralized ANDV (Fig. 4), indicating that pre-
existing cross-neutralizing antibodies were not contrib-
uting to the protective effect. However, all of the pro-
tected hamsters had relatively high homotypic PRNT
titers before ANDV challenge, and the unprotected ham-
sters had relatively low homotypic PRNT titers (DOBV-
preinfected hamster 2143 and 2147 had PRNT80% of ,20
nd 40, respectively), suggesting that a homotypic PRNT
iter is a surrogate marker of cross-protective immunity.
everal hamsters demonstrated ANDV NAb titers after
hallenge, indicating the animals were infected, but not
illed, by ANDV. Interestingly, five of eight hamsters pre-
iously infected with HTNV, three of eight previously
nfected with PUUV, and two of eight previously infected
ith SNV were completely protected against ANDV in-
ection as defined by the complete absence of an ANDV-
Ab response after ANDV challenge.
This is the first report of any hantavirus causing lethal
isease in an adult nonhuman animal. Not only is ANDV
ethal in hamsters, but also the disease resembles HPS
n humans (14). Similarities between the ANDV-associ-
ted disease in hamsters and HPS in humans are as
ollows: the clinical symptoms, including severe dys-
nea, rapid progression from first symptoms to death
,1 day in hamsters vs 4 days in humans infected with
NV (14)], fluid in the pleural cavity; the histopathology in
he lungs and spleen; and the incubation period of 10–24
ays in hamsters vs 12–27 days in humans (15). Differ-
ences between the hamster and human disease include
significant histopathology in the liver and readily detect-
able infectious virus in hamsters, which are not generally
present in HPS patients. This model can be used to
investigate the molecular basis of hantavirus disease
and might also contribute to our understanding of other
diseases that involve vascular leakage. In addition, be-
cause this is a lethal disease model, it will be possible to
evaluate the protective efficacy of candidate hantavirus
vaccines and antiviral drugs in a way never before pos-
sible. Our observation that a previous infection with het-
ero- or homotypic hantaviruses protected against ANDV
bodes well for development of effective HFRS and HPS
vaccines.
Methods. Viruses and cells. ANDV, strain Chile-
9717869, HTNV, strain 76-118 (16), SEOV, strain SR-11
(17), DOBV (18), and PUUV, strain K27 (19), and SNV,
strain CC107 (4) were propagated in Vero E6 cells (Vero
C1008; ATCC CRL 1586). The original ANDV, strain Chile-
9717869, stock was kindly provided by T. Ksiazek (Spe-
cial Pathogens Branch, Center for Disease Control, At-
lanta, GA), who isolated the virus from the kidneys and
lungs of Oligoryzomys longicaudatus captured by J. Mills
(Center for Disease Control, Atlanta) during an outbreak
in Chile (20). The original stock had been passaged four
t
ttimes in Vero E6 cells. We prepared a twice-plaque-
purified ANDV stock as follows. A hantavirus plaque
assay was performed on the original ANDV stock that
had been passaged an additional time in Vero E6 cells.
A well-isolated plaque was picked with a glass pasture
pipet and transferred to 0.5 ml cEMEM. After several
hours at 4°C, the plaque-pick was subjected to three
rapid freeze-thaws. This once-plaque-purified virus was
then titrated by plaque assay and the plaque-picking
procedure was repeated. The entire 0.5 ml of twice-
plaque-picked virus was then used to infect a T-25 flask
containing Vero E6 cells. After 12 days, the overlying
medium was collected. This passage 1 (P1) stock was
then used to infect Vero E6 monolayers in four T-150
flasks (multiplicity of infection was ;0.05). After 6 days,
the overlying medium was collected, pooled, and this
passage 2 (P2) stock was used in challenge experiments.
Intramuscular Injection of Virus into Hamsters. Four-
teen- to sixteen-week-old female Syrian hamsters
(Charles River) were injected intramuscularly (caudal
thigh) with 0.2 ml of virus diluted in phosphate-buffered
saline, pH 7.4. Injected hamsters were placed in isolator
units (one to four hamsters per cage) within a biosafety
level 4 (BSL-4) suite. Hamsters were observed two to
three times daily.
ELISA. Antinucleocapsid ELISA were performed as
described previously (13). The antigen was a histidine-
tagged truncated PUUV nucleocapsid fusion protein ex-
pressed from pPUUSXdelta (provided by F. Elgh, SMI,
Sweden) in Escherichia coli BL21 (DE3) (Novagen, Mad-
ison, WI) and affinity purified in Ni-NTA columns (Qiagen,
Valencia, CA).
PRNT. PRNT were performed essentially as previously
described (13). Heat-inactivated (56°C, 30 min) serum
samples were diluted in Eagle’s minimal essential me-
dium with Earle’s salts (EMEM) containing 10% heat-
inactivated fetal bovine serum, 10 mM HEPES pH 7.4;
and antibiotics [penicillin (100 U/ml), streptomycin (100
mg/ml), and gentamicin (50 mg/ml)] (cEMEM) and then
ombined with an equal volume (111 ml) of cEMEM
containing ;75 PFU of virus and 10% guinea pig com-
plement (Cat. No. ACL-4051, Accurate Chemical and Sci-
entific Corporation, Westbury, NY). This mixture was in-
cubated overnight at 4°C and then a plaque assay was
performed as described, using 7-day-old Vero E6 mono-
layers in sixwell plates. ANDV, HTNV, and SEOV PRNT
were stained with neutral red (GIBCO BRL) after 7 days
and DOBV, PUUV, and SNV PRNT were stained after 9
days. Plaques were counted 2 days (37°C) after staining.
Plaque Assay. The hantavirus plaque assay was per-
formed as follows. Samples diluted in cEMEM were
added, 200 ml per well, to sixwell plates (Costar) con-
aining 7-day-old Vero E6 monolayers. After a 1-h absorp-
ion at 37°C, 3 ml overlay medium [Earle’s basal minimal
n
e
13RAPID COMMUNICATIONessential medium, 10 mM HEPES, 0.6% agarose (Sea
Kem ME agarose, FMC Bioproducts, Rockland, ME), 8
mM L-glutamine, antibiotics] containing 10% FBS and 13
onessential amino acid mixture (GIBCO) was added to
ach well. Plates were incubated at 37°C in a CO2
incubator for 7 days (ANDV, HTNV, SEOV) or 9 days (SNV,
PUUV, DOBV) and then stained by adding 2 ml/well of
overlay medium containing 5% FBS and 5% neutral red
solution (GIBCO). Plaques were counted after 2 days at
37°C.
Preparation of Tissue for Histology. Tissues fixed in
neutral buffered Formalin were processed and embed-
ded in paraffin according to established protocols (21).
Immunolocalization of ANDV in hamster lungs was per-
formed with an alkaline phosphatase procedure (EnVi-
sion System; DAKO Corp., Carpinteria, CA or Vectastain
ABC-AP kit; Vector Laboratories, Burlingame, CA) ac-
cording to manufacturer’s directions. The primary anti-
body was an ANDV-specific pool of human sera obtained
from HPS cases in Argentina or hyperimmune rabbit sera
produced against SNV nucleocapsid. Negative controls
included replicate paraffin sections incubated with non-
immune human or rabbit serum in place of the primary
antibody and naive hamster tissue exposed to the pri-
mary antibody and to negative serum. Tissue sections
were pretreated in citrate buffer heated to 97°C in a
water bath for 30 min. Before adding the primary anti-
body, we exposed the tissues to a serum-free protein
block (DAKO) for 20 min. Both primary antibodies were
incubated on the tissue sections for 3 h or overnight at
4°C. A biotinylated goat anti-human IgG/IgM/IgA (Kirke-
gaard and Perry Laboratories) served as the secondary
antibody for the Vector Laboratories system. Goat anti-
rabbit and goat anti-mouse antibodies conjugated to an
alkaline phosphatase-labeled dextran polymer provided
with the EnVision kit served as the secondary antibody
for that system. The secondary antibodies were incu-
bated for 1 h (Vector Laboratories) or 30 min (EnVision
Kit) at room temperature. Sections were incubated for 50
min in the dark with the chromagenic substrate 6-bromo-
2-hydroxy-3-napthoic acid and levamisole to inhibit en-
dogenous alkaline phosphatase (HistoMark RED; Kirke-
gaard and Perry Labs.). Immunostained sections were
counterstained with hematoxylin, dehydrated, and cover
slips applied with Permount (Fisher Scientific).
Preparation of Tissue for Virus Titration. Approximately
250 mg of tissue was placed in a microfuge tube con-
taining 0.5 ml cEMEM. Samples were ground by hand
with a disposable pestle, subjected to three rapid freeze-
thaws, and spun in a microfuge at maximum speed for
5 s to pellet debris. Titers of infectious virus in the
supernatants were determined by plaque assay. Viral
titers are given as PFU per ml of tissue homogenate.ACKNOWLEDGMENTS
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accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. Opinions, interpretations, con-
clusions, and recommendations are those of the authors and are not
necessarily endorsed by the U.S. Army.
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